Skip to main content

Table 6 Causes of durvalumab discontinuation

From: Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC

 

Frequency

%

Still ongoing

7

29.2

Adverse events

3

12.5

Disease progression

9

37.5

All dose received (as planned)

5

20.8